Aug 21, 2024
Top Pharma Company in India | NATCO Pharma
Natco Pharma is a leading pharmaceutical company specializing in oncology, generic medications, and innovative solutions for crop health. Discover their high-quality healthcare products.
seen from China
seen from Sweden
seen from T1
seen from United Kingdom
seen from United States
seen from T1
seen from United States
seen from United Kingdom
seen from United States
seen from United States
seen from China
seen from France
seen from Türkiye
seen from United States
seen from United States
seen from China
seen from Russia
seen from United States
seen from China
seen from Malaysia
Top Pharma Company in India | NATCO Pharma
Natco Pharma is a leading pharmaceutical company specializing in oncology, generic medications, and innovative solutions for crop health. Discover their high-quality healthcare products.
Market this week 23-9-2022
Market this week 23-9-2022
SpiceJet stock plummets more than 3% as the airline places 80 pilots on unpaid leave. On September 21, a day after SpiceJet requested that 80 of its pilots take a three-month unpaid leave of absence, the company’s shares started 3.5 percent down. This action will assist rationalise the pilot strength in relation to the aircraft fleet and is in line with SpiceJet’s commitment of not laying off…
View On WordPress
Buy CLOMID (CLOMIPHENE) – 50MG / PER TAB – NATCO PHARMA
Clomid (Clomiphene Citrate) is a powerfully effective anti-estrogen officially classified as a Selective Estrogen Receptor Modulator (SERM). In many ways, it is very similar to another popular SERM in Nolvadex (Tamoxifen Citrate).
Price - $100.00
https://www.yourmuscleshop.com/product/clomiphene-clomid-50mg-tab/
Covid: Natco Pharma seeks approval for Molnupiravir capsules phase 3 trials
Natco Pharma Limited on Monday said it applied to the Central Drugs Standard Control Organization (CDSCO) for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of COVID-19 positive patients.
American pharma major Merck along with Ridgeback Biotherapeutics has developed Molnupiravir(MK-4482).
According to a press release from the city-based drug maker, pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication.
"Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy," it said.
NATCO is hoping that CDSCO would give emergency approval of this drug based on "compassionate use" for patients. Read More